Biography

Dr. Kim holds a Ph.D. in cancer cell biology from the Sungkyunkwan University in South Korea, which he earned in 2011. During his Postdoctoral fellow at UTSW Medical Center, his studies provided a clear rationale for the use of PARP inhibitors and identified novel pathway of PARP inhibitors for breast cancer treatment. Currently, Dr. Kim is seeking in-depth insights into how systemic metabolic conditions affect cancer progression, particularly in the context of breast cancer using a unique set of mouse models.

Research Interest
  • Breast Cancer
  • Dynamic Communication Between Tumor and Adipose Tissue
  • Obesity

Publications

Featured Publications LegendFeatured Publications

PARPs and ADP-ribosylation in RNA biology: from RNA expression and processing to protein translation and proteostasis.
Kim DS, Challa S, Jones A, Kraus WL, Genes Dev. 2020 03 34 5-6 302-320
Activation of PARP-1 by snoRNAs Controls Ribosome Biogenesis and Cell Growth via the RNA Helicase DDX21.
Kim DS, Camacho CV, Nagari A, Malladi VS, Challa S, Kraus WL, Mol. Cell 2019 Sep 75 6 1270-1285.e14
PARP-1 Controls the Adipogenic Transcriptional Program by PARylating C/EBPß and Modulating Its Transcriptional Activity.
Luo X, Ryu KW, Kim DS, Nandu T, Medina CJ, Gupte R, Gibson BA, Soccio RE, Yu Y, Gupta RK, Kraus WL Mol. Cell 2017 Jan 65 2 260-271
Discovery, Annotation, and Functional Analysis of Long Noncoding RNAs Controlling Cell-Cycle Gene Expression and Proliferation in Breast Cancer Cells.
Sun M, Gadad SS, Kim DS, Kraus WL Mol. Cell 2015 Aug 59 4 698-711
New Facets in the Regulation of Gene Expression by ADP-Ribosylation and Poly(ADP-ribose) Polymerases.
Ryu KW, Kim DS, Kraus WL Chem. Rev. 2015 Jan
Cancer cells promote survival through depletion of the von Hippel-Lindau tumor suppressor by protein crosslinking.
Kim DS, Choi YB, Han BG, Park SY, Jeon Y, Kim DH, Ahn ER, Shin JE, Lee BI, Lee H, Hong KM, Kim SY, Oncogene 2011 Dec 30 48 4780-90
Transglutaminase 2 gene ablation protects against renal ischemic injury by blocking constant NF-?B activation.
Kim DS, Kim B, Tahk H, Kim DH, Ahn ER, Choi C, Jeon Y, Park SY, Lee H, Oh SH, Kim SY, Biochem. Biophys. Res. Commun. 2010 Dec 403 3-4 479-84
I-kappaBalpha depletion by transglutaminase 2 and mu-calpain occurs in parallel with the ubiquitin-proteasome pathway.
Kim DS, Han BG, Park KS, Lee BI, Kim SY, Bae CD, Biochem. Biophys. Res. Commun. 2010 Aug 399 2 300-6
Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition.
Kim DS, Park KS, Jeong KC, Lee BI, Lee CH, Kim SY, Cancer Lett. 2009 Jan 273 2 243-9
Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation.
Kim DS, Park SS, Nam BH, Kim IH, Kim SY, Cancer Res. 2006 Nov 66 22 10936-43